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I ntramedullary
spinal cord tumors (IMSCTs) are rare neoplasms of the CNS and have been a significant clinical challenge due to the lack of a clear standard of care, limited therapeutic options, and challenges of drug delivery. IMSCTs account for 2%-4% of all CNS tumors, with ependymoma being the most common in adults and astrocytomas being the most common in children and ado lescents. 10 Overall, ependymomas are the most frequent IMSCTs, followed by astrocytomas and then miscella neous tumors including hemangioblastomas, ganglioglio mas, germinomas, primary CNS lymphomas, and melano mas (Table 1) . Although rare, IMSCTs can also develop as a result of metastasis from a primary malignancy.
While most IMSCTs are benign, lowgrade (WHO Grades I and II) tumors, many vary in histology and 7%-30% of astrocytomas are considered malignant. 11,13 IMSCTs can be found in any location throughout the length of the spinal cord; however, they are most common at the cervi cal level (33%), followed by the thoracic (26%) and lumbar (24%) levels. 29 The higher incidence of IMSCTs at the cer vical level may be related to the higher level of gray matter present at that level. MRI is recommended for the identi fication and evaluation of IMSCTs, with intensities and contrastenhancement varying depending on the tumor type and signal.
The most common presenting symptom of IMSCT is back pain, which may be diffuse or radicular in nature. Di agnosis is especially difficult in children, where IMSCTs may remain asymptomatic for a long period of time or cause nonspecific complaints. 28 The character of the pain varies, but is commonly reported to worsen at night. IMSCTs can also impinge on somatosensory and motor systems, caus ing dys and paresthesias, spasticity, and weakness. Loss of bowel and bladder function can also occur at a later stage and is the least common presenting symptom. 54 Symptoms in children may be perceived as clumsiness or attributed to ABBREVIATIONS BSCB = blood-spinal cord barrier; CED = convection-enhanced delivery; EGFR = epidermal growth factor receptor; Fn14 = protein fibroblast growth factor-inducible 14; GCT = germ cell tumor; GTR = gross-total resection; IMSCT = intramedullary spinal cord tumor; STR = subtotal resection; VEGF = vascular endothelial growth factor; VHL = von Hippel-Lindau. Intramedullary spinal cord tumors have low incidence rates but are associated with difficult treatment options. The majority of patients with these tumors can be initially treated with an attempted resection. Unfortunately, those patients who cannot undergo gross-total resection or have subtotal resection are left with few treatment options such as radiotherapy and chemotherapy. These adjuvant treatments, however, are associated with the potential for significant adverse side effects and still leave patients with a poor prognosis. To successfully manage these patients and improve both their quality of life and prognosis, novel treatment options must be developed to supplement subtotal resection. New research is underway investigating alternative therapeutic approaches for these patients, including directed, localized drug delivery and nanomedicine techniques. These and other future investigations will hopefully lead to promising new therapies for these devastating diseases. trivial injuries, and scoliosis is present in onethird of pa tients. 28 Evidencebased treatment of IMSCTs (Table 2) primar ily involves resection, with radiotherapy and chemother apy often reserved for tumor recurrence, highgrade and infiltrative tumors, or when resection is contraindicated. Preoperative neurological status and tumor histology are considered the best predictors of outcome, with tumor his tology shown to be predictive of extent of resection, func tional neurological outcomes, and recurrence. 30 Resection is generally considered a good predictor of outcome. Re cent studies, however, have shown that surgical interven tion for the management of astrocytoma is associated with higher rates of longterm neurological complications with no derived benefit for patients. 5 The standard of care for most cases of IMSCT is resec tion, which has improved with the development of modern neurosurgical instrumentation, use of the operating micro scope, as well as the measurement of intraoperative motor and somatosensory evoked potentials. However, resection of IMSCT is generally dependent on the presence or ab sence of a clear plane of dissection. While ependymomas typically have a clear plane between the tumor and spinal cord parenchyma, astrocytomas tend to be more infiltra tive, lacking a good plane of dissection. 14 This limits the ability for grosstotal resection (GTR) for intramedullary astrocytomas, as any attempt at GTR may damage spinal pathways, leading to postoperative neurological deficits involving both motor and sensory systems.
Adjuvant radiotherapy is recommended when resec tion is contraindicated, or for highgrade tumors that are not amenable to GTR. The role of radiotherapy, though, is controversial, as there have been reports that suggest a positive outcome while others suggest no benefit de spite its routine use in the clinical setting. 60 Additionally, radiotherapy can have several adverse effects, including radiation myelopathy, impaired spine growth, spinal de formities, radiation necrosis, vasculopathy, changes to the normal spine parenchyma, and a 25% risk of secondary tumors in 30 years. 6,10 These longerterm consequences can be particularly adverse in children and adolescents.
Since children are more sensitive to the adverse effects of IMSCTs, the role of chemotherapy has gained further appreciation. Chemotherapy has historically been used only when resection and adjuvant radiotherapy were con traindicated or unsuccessful. 10 Some of the limitations of chemotherapeutic agents include the inability of large mol ecules to bypass the blood-spinal cord barrier (BSCB), 
